Global Information
회사소개 | 문의

중국의 세보프루렌 시장

Investigation Report on Sevoflurane in China, 2018-2022

리서치사 China Research and Intelligence
발행일 2018년 06월 상품 코드 337518
페이지 정보 영문 30 Pages
가격
US $ 2,200 ₩ 2,500,000 Unprintable PDF (Single User License)
US $ 3,300 ₩ 3,750,000 Printable & Editable PDF (Enterprisewide License)


중국의 세보프루렌 시장 Investigation Report on Sevoflurane in China, 2018-2022
발행일 : 2018년 06월 페이지 정보 : 영문 30 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

세보프루렌(Sevoflurane)은 중국 시장에 진출한 이후 급성장하고 있습니다. 연간 매출액은 2005년의 400만 위안에서 2014년에는 4억 위안에 달하며 CAGR로 71%의 성장을 달성했습니다.

중국의 세보프루렌 시장에 대해 조사분석했으며, 시장 규모, 시장 점유율, 소매가격, 주요 제조업체, 시장 전망 등에 대한 체계적인 정보를 정리하여 전해드립니다.

제1장 세보프루렌 관련 개념

  • 적응
  • 세계 시장의 판매 상황

제2장 중국의 세보프루렌 시장 개요

  • 중국의 세보프루렌 특허·승인 상황
  • 주요 제조업체
  • 시장 규모

제3장 중국의 세보프루렌 판매 상황 분석

  • 매출액
  • 매출 수량

제4장 중국 주요 세보프루렌 제조업체의 시장 점유율 분석

  • 시장 점유율 : 매출액별
  • 시장 점유율 : 매출 수량별

제5장 중국의 세보프루렌 제형별 분석

  • 시장 점유율(제형별) : 매출액별
  • 시장 점유율(제형별) : 매출 수량별

제6장 중국 세보프루렌의 병원용 기준가격

  • Shanghai Hengrui Pharmaceutical Co., Ltd
  • MARUISHI PHARMACEUTICAL CO.,LTD.(일본)
  • Jiangsu Hengrui Medicine Co., Ltd
  • Baxter Healthcare Corporation (미국)
  • Lunan Better Pharmaceutical Co., Ltd

제7장 중국 세보프루렌 시장의 주요 제조업체

  • Shanghai Hengrui Pharmaceutical Co., Ltd
  • MARUISHI PHARMACEUTICAL CO.,LTD.(일본)
  • Jiangsu Hengrui Medicine Co., Ltd
  • Baxter Healthcare Corporation (미국)
  • Lunan Better Pharmaceutical Co., Ltd

제8장 중국의 세보프루렌 시장 전망

  • 시장 규모 예측
  • 경쟁 구도 예측

도표

KSA 15.09.02

Description

Sevoflurane is an inhaled general anesthetic featured with rapid induction and quick wake-up of patients. It has slight inhibition on circulation, little effect on liver and kidney function and a clear myocardial protective effect. Therefore, sevoflurane has now become the main inhaled anesthetic and is particularly suitable for patients with myocardial damage.

According to CRI's analysis, in 1996, the sevoflurane of Abbott entered the Chinese market, but currently Abbott holds a very small market share. The approved imported sevoflurane also comes from Maruishi and MARUKO of Japan and Baxter of the United States. In 2007 and 2008, CFDA approved the inhaled solution sevoflurane of Shanghai Hengrui Pharmaceuticals and Lunan Better Pharmaceutical to go public in China. Gradually, domestic sevoflurane dominates the Chinese market.

As the environmental pollution intensifies and the population ages, the demand for medical services is rapidly rising. The hospitalization increased from 115 million in 2008 to 227 million in 2016, with the CAGR up to 7.8%. Among them, one quarter of patients was hospitalized for surgery. The increasing amount of surgery boosts the demand for narcotic drugs.

CRI market research shows that sales value of sevoflurane in the Chinese market rose from less than CNY 4 million in 2005 to CNY 82.8 million in 2007 and to CNY 633 million in 2017. The CAGR during 2007 to 2017 reached about 22.6%.

According to CRI's market research, the major market share holders in China are Maruishi, Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd., Baxter, MARUKO and Lunan Better Pharmaceutical Co., Ltd. In terms of sales volume, Shanghai Hengrui Pharmaceutical holds the biggest market occupancy, which in 2017 was about 55%.

It is expected that with the increasing surgery in China from 2018 to 2022, the demand for narcotic drugs will continue to increase, creating a promising future market for sevoflurane.

Topics Covered:

Indication of sevoflurane

Market size of sevoflurane

Major sevoflurane manufacturers in the Chinese market

Competition pattern of sevoflurane in China

Sale price of sevoflurane in China

Prospects of sevoflurane

Table of Contents

Table of Contents

1 Sevoflurane-related Concepts

  • 1.1 Indication
  • 1.2 Development of Sevoflurane in Chinese Market

2 Market Overview of Sevoflurane

  • 2.1 Patents and Drug Approval of Government
  • 2.2 Major Manufacturers
  • 2.3 Market Size

3 Analysis of Sevoflurane Sales in China, 2013-2017

  • 3.1 Sales Value
    • 3.1.1 Overall Sales
    • 3.1.2 Sales Value in Different Regions
  • 3.2 Sales Volume
    • 3.2.1 Overall Volume
    • 3.2.2 Sales Volume by Region
  • 3.3 Market Share of Sevoflurane by Dosage Form
    • 3.3.1 Market Share of Sevoflurane by Sales Value
    • 3.3.2 Market Share of Sevoflurane by Sales Volume

4 Market Share of Sevoflurane Manufacturers in China, 2013-2017

  • 4.1 Market Share by Sales Value
  • 4.2 Market Share by Sales Volume

5 Major Sevoflurane Manufacturers in Chinese Market, 2017-2018

  • 5.1 Maruishi
  • 5.2 Shanghai Hengrui Pharmaceutical Co., Ltd.
  • 5.3 Jiangsu Hengrui Medicine Co., Ltd.
  • 5.4 Baxter
  • 5.5 Maruko Pharmaceutical Co., Ltd.
  • 5.6 Lunan Better Pharmaceutical Co., Ltd.

6 Reference Sale Price of Sevoflurane Manufacturers in Hospitals, 2017-2018

  • 6.1 Maruishi
  • 6.2 Shanghai Hengrui Pharmaceutical Co., Ltd.
  • 6.3 Jiangsu Hengrui Medicine Co., Ltd.
  • 6.4 Baxter
  • 6.5 Maruko Pharmaceutical Co., Ltd.
  • 6.6 Lunan Better Pharmaceutical Co., Ltd.

7 Prospects of Sevoflurane in China, 2018-2022

  • 7.1 Forecast on Market Size
  • 7.2 Market Prospects

Part of Charts

  • Chart Drug Approval of Government on Sevoflurane in China
  • Chart Sales of Sevoflurane in China
  • Chart Sales Value of Sevoflurane in China, 2007-2017
  • Chart Sales volume of Sevoflurane in China, 2007-2017
  • Chart Market Share of Top 6 Sevoflurane Manufacturers in Sales Value, 2013-2017
  • Chart Market Share and Sales Value of Maruishi in China, 2013-2017
  • Chart Market Share and Sales Value of Shanghai Hengrui Pharmaceutical in China, 2013-2017
  • Chart Market Share and Sales Value of BAXTER in China, 2013-2017
  • Chart Sevoflurane Sale Price of Maruishi in Several Chinese Cities, 2017-2018
  • Chart Sevoflurane Sale Price of Shanghai Hengrui Pharmaceutical in Several Chinese Cities, 2017-2018
  • Chart Sevoflurane Sale Price of Jiangsu Hengrui Medicine in Several Chinese Cities, 2017-2018
  • Chart Forecast on Sevoflurane Market Size in China, 2018-2022
Back to Top
전화 문의
이용안내
 
BCC Research